KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Finished Goods (2023 - 2025)

Historic Finished Goods for Aurinia Pharmaceuticals (AUPH) over the last 3 years, with Q3 2025 value amounting to $1.4 million.

  • Aurinia Pharmaceuticals' Finished Goods changed N/A to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year change of. This contributed to the annual value of $903000.0 for FY2024, which is 5488.85% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Finished Goods stood at $1.4 million.
  • Over the past 5 years, Aurinia Pharmaceuticals' Finished Goods peaked at $3.7 million during Q1 2025, and registered a low of $583000.0 during Q4 2023.
  • For the 3-year period, Aurinia Pharmaceuticals' Finished Goods averaged around $1.8 million, with its median value being $1.4 million (2025).
  • The largest annual percentage gain for Aurinia Pharmaceuticals' Finished Goods in the last 5 years was 5488.85% (2024), contrasted with its biggest fall of 5488.85% (2024).
  • Over the past 3 years, Aurinia Pharmaceuticals' Finished Goods (Quarter) stood at $583000.0 in 2023, then soared by 54.89% to $903000.0 in 2024, then soared by 53.38% to $1.4 million in 2025.
  • Its Finished Goods stands at $1.4 million for Q3 2025, versus $2.6 million for Q2 2025 and $3.7 million for Q1 2025.